Moderna's Flu Vaccine Gains Favor with FDA Before Advisory Committee Meeting
In recent biotech developments, the FDA seems receptive to Moderna's flu vaccine as UniQure prepares to submit its Huntington's therapy for approval, and Eli Lilly acquires 4E Therapeutics.
Editorial Staff
1 min read
Updated about 7 hours ago
The FDA appears to be open to considering Moderna's flu vaccine ahead of an upcoming advisory committee meeting. This development could signal a positive trajectory for the vaccine's approval process.
In other news, UniQure is set to submit its therapy for Huntington's disease for regulatory approval, marking a significant step in the treatment of this condition.
Additionally, Eli Lilly has made headlines with its acquisition of 4E Therapeutics, further expanding its portfolio in the biotech sector.